Precision Medicine

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.

With a new $17.5M financing, Forlong Biotechnology accelerates its promising IL-15 and IL-18 cancer drugs, aiming to redefine post-PD-1 immunotherapy.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

The Karen Toffler Charitable Trust names Deborah Westphal its first CEO, signaling a strategic shift to accelerate neuroscience innovation for a new generation.

New research on the gut-brain axis and smarter antibiotic use is transforming veterinary medicine, moving from theory to practice for healthier pets.

Europe's top cancer center adopts an AI orchestration platform, aiming to cut wait times, boost efficiency, and reshape the patient journey.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

A PIF company becomes the first Saudi entity to join a top global genomics forum, a strategic move under Vision 2030 to shape the future of healthcare.

Quince Therapeutics' drug LAM-001 posts strong Phase 2a data, showing meaningful functional gains for patients with severe pulmonary hypertension.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

A new partnership with AI firm Basepath Health will help Children's Mercy treat five times more children with complex and rare genetic diseases.

New FolinicActive™ offers a multi-pathway folate for the 15-25% of adults who report adverse effects from standard L-methylfolate supplements.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

A new partnership between Hong Kong's PAIR and the UK's Cambridge NeuroWorks aims to accelerate brain health innovations through a global seminar series.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

A new partnership uses AI to eliminate costly subjectivity in brain disorder research, promising to accelerate new treatments and improve data integrity.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.